These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 31757644)

  • 1. Prognostic implications of N-terminal pro-B-type natriuretic peptide in patients with normal left ventricular ejection fraction undergoing transcatheter aortic valve implantation.
    Seoudy H; Kuhn C; Frank J; Eden M; Rangrez AY; Lutter G; Frey N; Frank D
    Int J Cardiol; 2020 Feb; 301():195-199. PubMed ID: 31757644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different impact of aortic regurgitation assessed by aortic root angiography after transcatheter aortic valve implantation according to baseline left ventricular ejection fraction and N-terminal pro-B-type natriuretic peptide.
    Kaneko H; Hoelschermann F; Schau T; Tambor G; Neuss M; Butter C
    Cardiovasc Interv Ther; 2018 Jul; 33(3):232-238. PubMed ID: 28567700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term prognostic value and serial changes of plasma N-terminal prohormone B-type natriuretic peptide in patients undergoing transcatheter aortic valve implantation.
    Ribeiro HB; Urena M; Le Ven F; Nombela-Franco L; Allende R; Clavel MA; Dahou A; Côté M; Laflamme J; Laflamme L; DeLarochellière H; DeLarochellière R; Doyle D; Dumont E; Bergeron S; Pibarot P; Rodés-Cabau J
    Am J Cardiol; 2014 Mar; 113(5):851-9. PubMed ID: 24528616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of N-terminal pro-B-type natriuretic peptide response on long-term prognosis after transcatheter aortic valve implantation for severe aortic stenosis and heart failure.
    Kaneko H; Hoelschermann F; Tambor G; Okamoto M; Neuss M; Butter C
    Heart Vessels; 2019 May; 34(5):777-783. PubMed ID: 30443765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Periprocedural Changes of NT-proBNP Are Associated With Survival After Transcatheter Aortic Valve Implantation.
    Seoudy H; Frank J; Neu M; Güßefeld N; Klaus Y; Freitag-Wolf S; Lambers M; Lutter G; Dempfle A; Rangrez AY; Kuhn C; Frey N; Frank D
    J Am Heart Assoc; 2019 Feb; 8(3):e010876. PubMed ID: 30686097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal pro-B-type natriuretic peptide-ratio predicts mortality after transcatheter aortic valve replacement.
    Stähli BE; Gebhard C; Saleh L; Falk V; Landmesser U; Nietlispach F; Maisano F; Lüscher TF; Maier W; Binder RK
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1240-7. PubMed ID: 25511571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution and prognostic value of N-terminal brain natriuretic peptide in predicting 1-year mortality in patients following transcatheter aortic valve implantation.
    Elhmidi Y; Bleiziffer S; Piazza N; Ruge H; Krane M; Deutsch MA; Hettich I; Voss B; Mazzitelli D; Lange R
    J Invasive Cardiol; 2013 Jan; 25(1):38-44. PubMed ID: 23293174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-procedural N-terminal pro-brain natriuretic peptide predicts one-year mortality after transcatheter aortic valve implantation.
    Vale NC; Campante Teles R; Madeira S; Brito J; Sousa Almeida M; Nolasco T; Abecasis J; Rodrigues G; Carmo J; Furstenau M; Ribeiras R; Neves JP; Mendes M
    Rev Port Cardiol (Engl Ed); 2018 Jan; 37(1):67-73. PubMed ID: 29317115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Prognostic Value of High-Sensitivity Troponin T Added to N-Terminal Pro Brain Natriuretic Peptide Plasma Levels Before Valve Replacement for Severe Aortic Stenosis.
    Barbieri F; Senoner T; Adukauskaite A; Dobner S; Holfeld J; Semsroth S; Lambert T; Zweiker D; Theurl T; Rainer PP; Schmidt A; Feuchtner GM; Steinwender C; Hoppe UC; Hintringer F; Bauer A; Müller S; Grimm M; Pfeifer BE; Dichtl W
    Am J Cardiol; 2019 Dec; 124(12):1932-1939. PubMed ID: 31699359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is elevation of N-terminal pro-B-type natriuretic peptide at discharge associated with 2-year composite endpoint of all-cause mortality and heart failure hospitalisation after transcatheter aortic valve implantation? Insights from a multicentre prospective OCEAN-TAVI registry in Japan.
    Mizutani K; Hara M; Nakao M; Okai T; Kajio K; Murakami T; Shibata T; Yoshiyama M; Naganuma T; Yamanaka F; Higashimori A; Tada N; Takagi K; Araki M; Ueno H; Tabata M; Shirai S; Watanabe Y; Yamamoto M; Hayashida K
    BMJ Open; 2018 Aug; 8(8):e021468. PubMed ID: 30121598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-terminal pro-B-type natriuretic peptide is associated with clinical outcomes after transcatheter aortic valve replacement.
    Yu J; Wang W
    J Cardiothorac Surg; 2023 Oct; 18(1):286. PubMed ID: 37817246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline NT-proBNP Accurately Predicts Symptom Response to Transcatheter Aortic Valve Implantation.
    Allen CJ; Joseph J; Patterson T; Hammond-Haley M; McConkey HZR; Prendergast BD; Marber M; Redwood SR
    J Am Heart Assoc; 2020 Dec; 9(23):e017574. PubMed ID: 33241754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated N-terminal pro C-type natriuretic peptide is associated with mortality in patients undergoing transcatheter aortic valve replacement.
    Hu P; Chen H; Wang LH; Jiang JB; Li JM; Tang MY; Guo YC; Zhu QF; Pu ZX; Lin XP; Ng S; Liu XB; Wang JA
    BMC Cardiovasc Disord; 2022 Apr; 22(1):164. PubMed ID: 35413789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated growth differentiation factor 15 levels predict outcome in patients undergoing transcatheter aortic valve implantation.
    Krau NC; Lünstedt NS; Freitag-Wolf S; Brehm D; Petzina R; Lutter G; Bramlage P; Dempfle A; Frey N; Frank D
    Eur J Heart Fail; 2015 Sep; 17(9):945-55. PubMed ID: 26230285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does residual aortic regurgitation after transcatheter aortic valve implantation increase mortality in all patients? The importance of baseline natriuretic peptides.
    Borz B; Durand E; Godin M; Tron C; Canville A; Hauville C; Bauer F; Cribier A; Eltchaninoff H
    Int J Cardiol; 2014 May; 173(3):436-40. PubMed ID: 24679693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of left ventricular function with tissue Doppler echocardiography and of B-type natriuretic peptide levels in patients undergoing transcatheter aortic valve implantation.
    Yüksel IO; Arslan S; Cagirci G; Koklu E; Ureyen CM; Bayar N; Kucukseymen S; Kus G; Guven R
    Rev Port Cardiol; 2017 May; 36(5):377-383. PubMed ID: 28495181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of paravalvular leaks on biomarkers and survival after transcatheter aortic valve implantation.
    Schewel D; Frerker C; Schewel J; Wohlmuth P; Meincke F; Thielsen T; Kreidel F; Kuck KH; Schäfer U
    Catheter Cardiovasc Interv; 2015 Feb; 85(3):502-14. PubMed ID: 24259366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes From Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis and Left Ventricular Ejection Fraction Less Than 30%: A Substudy From the TOPAS-TAVI Registry.
    Maes F; Lerakis S; Barbosa Ribeiro H; Gilard M; Cavalcante JL; Makkar R; Herrmann HC; Windecker S; Enriquez-Sarano M; Cheema AN; Nombela-Franco L; Amat-Santos I; Muñoz-García AJ; Garcia Del Blanco B; Zajarias A; Lisko JC; Hayek S; Babaliaros V; Le Ven F; Gleason TG; Chakravarty T; Szeto W; Clavel MA; de Agustin A; Serra V; Schindler JT; Dahou A; Salah-Annabi M; Pelletier-Beaumont E; Côté M; Puri R; Pibarot P; Rodés-Cabau J
    JAMA Cardiol; 2019 Jan; 4(1):64-70. PubMed ID: 30566185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How low is "low-flow" in aortic stenosis? A retrospective analysis of patients with true low-flow/low-gradient aortic stenosis undergoing TAVI.
    Kücken T; Edlinger C; Okamoto M; Bannehr M; Jirak P; Lichtenauer M; Haase-Fielitz A; Krizanic F; Butter C
    Minerva Med; 2021 Jun; 112(3):322-328. PubMed ID: 32700869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk prediction in patients with low-flow, low-gradient aortic stenosis and reduced ejection fraction undergoing TAVI.
    Ludwig S; Goßling A; Seiffert M; Westermann D; Sinning JM; Sugiura A; Adam M; Mauri V; Frank D; Seoudy H; Rudolph T; Potratz M; Conradi L; Schofer N
    Open Heart; 2022 Jan; 9(1):. PubMed ID: 34987075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.